GLP-1 receptor agonist liraglutide reverses long-term atypical antipsychotic treatment associated behavioral depression and metabolic abnormalities in rats
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Mood disorder patients that are on long-term atypical antipsychotics treatment frequently experience metabolic dysfunctions. In addition to this, accumulating evidences points to increased risk of structural abnormalities, brain volume changes, altered neuroplasticity and behavioral depression with long-term antipsychotics use. However, there is paucity of preclinical evidences for long-term antipsychotic associated depression-like behavior. The objectives of the present study were: (1) to evaluate influence of long-term antipsychotic (olanzapine) treatment on rat behavior in forced swim test (FST) as a model for depression and; (2) to examine impact of glucagon-like peptide 1 (GLP-1) receptor agonist liraglutide - an antidiabetic medication for type II diabetes, on long-term olanzapine associated metabolic and behavioral changes in rats. Daily olanzapine treatment (0.5 mg/kg; p.o.) for 8-9 weeks significantly increased body weights, food and water intake, plasma cholesterol and triglycerides and immobility time in FST with parallel reduction in plasma HDL cholesterol levels. These results points to development of metabolic abnormalities and depression-like behavior with long-term olanzapine treatment. Acute liraglutide (50 μg/kg; i.p.) and imipramine (10 mg/kg, i. p.) treatment per se significantly decreased duration of immobility in FST compared to vehicle treated rats. Additionally, 3-week liraglutide treatment (50 μg/kg; i.p., daily) partially reversed metabolic abnormalities and depression-like behavior with long-term olanzapine-treatment in rats. None of these treatment regimens affected locomotor behavior of rats. In summary, add-on GLP-1 receptor agonists promise novel alternatives to counteract long-term antipsychotics associated behavioral and metabolic complications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.
De Hert, M., Detraux, J., van Winkel, R., Yu, W., & Correll, C. U. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.156 · Cited by 1,145 · cited 1×
“Long-term olanzapine treatment can induce and/or aggravate metabolic adverse effects in schizophrenics (De et al. 2012; De et al. 2011).”
BackgroundAnimal Model of Depression: I. Review of Evidence: Implications for Research
McKinney, W. T. (1969) · Archives of General Psychiatry · doi:10.1001/archpsyc.1969.01740200112015 · Cited by 727
Agersø, H., Jensen, L. B., Elbrønd, B., Rolan, P., & Zdravkovic, M. (2002) · Diabetologia · doi:10.1007/s00125-001-0719-z · Cited by 510 · cited 3×
“GLP-1 is secreted by the intestinal L-cells in response to ingested carbohydrates and fats (Agerso et al. 2002).”
BackgroundInfluentialGlucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats
Farilla, L., Hui, H., Bertolotto, C., Kang, E., Bulotta, A., Di Mario, U., & Perfetti, R. (2002) · Endocrinology · doi:10.1210/en.2002-220405 · Cited by 502 · cited 1×
“GLP-1 is also known for β-cell proliferation and inhibition of pancreatic β-cell apoptosis (Farilla et al. 2002) and small bowel motility and gastric emptying (Tolessa et al. 1998).”
BackgroundKim, S., Moon, M., & Park, S. (2009) · Journal of Endocrinology · doi:10.1677/joe-09-0132 · Cited by 263 · cited 2×
“GLP-1 receptor agonist also exhibit neuroprotective effect, improve locomotor activity (Kim et al. 2009), reverse behavioral, noradrenergic (Abuirmeileh et al.”
BackgroundThe glucagon-like peptide 1 analogue Exendin-4 attenuates alcohol mediated behaviors in rodents
Egecioglu, E., Steensland, P., Fredriksson, I., Feltmann, K., Engel, J. A., & Jerlhag, E. (2013) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2012.11.009 · Cited by 207 · cited 1×
“…noradrenergic (Abuirmeileh et al. 2012; Rampersaud et al. 2012a; Rampersaud et al. 2012a; Rampersaud et al. 2012b) and serotonergic deficits (Brunetti et al. 2008), alcohol mediated behaviors (Egecioglu et al. 2013) and amphetamineinduced hyperlocomotion in rodents (Erreger et al. 2012).”
BackgroundLando, H. M., Alattar, M., & Dua, A. P. (2012) · Endocrine Practice · doi:10.4158/ep11290.or · Cited by 102 · cited 2×
“Recent evidences suggests that GLP-1 and its receptor agonists may have effects beyond regulation of food intake behavior viz. regulation of sleep patterns, anti-inflammatory and neuroprotective activities (Benedict et al. 2013; Lando et al. 2012; Liu et al. 2011; Teramoto et al. 2011).”
BackgroundEbdrup, B. H., Knop, F. K., Ishøy, P. L., Rostrup, E., Fagerlund, B., Lublin, H., & Glenthøj, B. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-92 · Cited by 34
Cited by
Athauda, D., & Foltynie, T. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.01.013 · Cited by 383
Anderberg, R. H., Richard, J. E., Hansson, C., Nissbrandt, H., Bergquist, F., & Skibicka, K. P. (2016) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2015.11.021 · Cited by 170
McIntyre, R. S., Mansur, R. B., Rosenblat, J. D., & Kwan, A. T. H. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2295397 · Cited by 126
Kim, Y.-K., Kim, O. Y., & Song, J. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01270 · Cited by 109
Glucagon-Like Peptide-1 (GLP-1) in the Integration of Neural and Endocrine Responses to Stress
Diz-Chaves, Y., Herrera-Pérez, S., González-Matías, L. C., Lamas, J. A., & Mallo, F. (2020) · Nutrients · doi:10.3390/nu12113304 · Cited by 84
Metadata
- Authors
- Sharma, A. N., Ligade, S. S., Sharma, J. N., Shukla, P., Elased, K. M., & Lucot, J. B.
- Venue
- Metabolic Brain Disease
- Published
- 2014-07-15
- Volume
- 30
- Issue
- 2
- Pages
- 519-527
- ISSN
- 0885-7490 (ISSN-L)
- 1573-7365
- OpenAlex
- W2038193252
- Cited by
- 66
- References
- 8
- FWCI
- 2.47
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: GLP-1 receptor agonist liraglutide reverses long-term atypical antipsychotic treatment associated behavioral depression and metabolic abnormalities in rats. https://app.cochat.ai/papers/10.1007/s11011-014-9591-7
- The paper
- Sharma, A. N., Ligade, S. S., Sharma, J. N., Shukla, P., Elased, K. M., & Lucot, J. B. (2015). GLP-1 receptor agonist liraglutide reverses long-term atypical antipsychotic treatment associated behavioral depression and metabolic abnormalities in rats. Metabolic Brain Disease. https://doi.org/10.1007/s11011-014-9591-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.